With an increased need for high quality in vitro diagnostic medical devices (IVDs), the In Vitro Diagnostic Regulation (IVDR, 2017/746) was entered into force for all IVDs in 2017 with a five-year transition period. The end of this transition period is May 2022, leaving manufacturers with very little time before their technical documentation needs to be updated to comply with the regulations and meet the new, more stringent requirements. This blog will answer the top critical questions, and more information about Medical Devices & Diagnostics can be found here.
What will be the impact of this change for manufacturers with products in the EU and what do we expect for US markets? Having a comprehensive and efficient strategy will help you ensure a rapid and successful pathway to market access. Here are answers to the top critical questions to prepare for the new regulation.
The quality management adjustments should be made as soon as possible, per article 10, paragraph 8. Performance evaluation should be addressed to the IVDR level ASAP as well.
Still some time to go before going live for other parties than the NB and CAs. No workaround necessary at this time.
As referenced in article 10 and paragraph 8, start updating the technical documentation to the IVDR level sooner rather than later.
Don’t forget thorough software validation according to the standards, and don’t forget about GDPR.
The MEDDEV 2.7. series is applicable to medical devices, not IVDs. But yes, some GSPR must be addressed by the performance evaluation process.
We have conducted gap assessment projects to understand and prioritize what needs to be done to address IVDR/MDR compliance. We have also provided subject matter experts to run mock audits or address specific needs regarding IVDR/MDR compliance (e.g., PMSS, Clinical or Performance Compliance). Finally, we have provided overarching project management support to successfully oversee and drive these programs to completion.
Yes, that is correct!
If you have a question we didn’t answer here, connect with our team and learn more about our solutions to successfully prepare for the new regulations. With the acquisition of Treximo, ProPharma Group has extended our global expertise to ensure medical device and diagnostics products are successfully and rapidly brought to market.
March 3, 2021
Yes, there is a light at the end of the long, dark COVID-19 tunnel, and people’s lives will return to a state of normalcy. However, what will the new state of normalcy look like in a post COVID-19...
November 19, 2020
About 15 years ago, I was a project management director responsible for moving monoclonal antibodies (MABs) from Phase III clinical to commercial manufacturing. I had the distinct pleasure of working...
November 15, 2018
Increasing safe and effective patient treatment opportunities for the future is one of the driving forces behind ProPharma Group’s business. It’s also the driving force behind why many individuals...